Antiviral Compounds Targeting HBV Capsid Formation and cccDNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) infections are limited by low cure rates, drug resistance, and the persistence of covalently closed circular DNA (cccDNA) in infected hepatocytes, necessitating the development of new antiviral agents that can effectively reduce viral load and target cccDNA.
Innovation Solution
Development of specifically substituted aromatic/heteroaromatic compounds and their pharmaceutically acceptable salts or prodrugs, which can be administered to treat, cure, or prevent HBV infections by inhibiting capsid formation and reducing cccDNA levels, potentially used in combination with other antiviral agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If nucleoside analogs (3TC, entecavir, tenofovir) are used to treat HBV, then viral load is reduced, but drug resistance emerges and cure rates remain low
Solution Approach 1:
The patent employs a combination therapy approach, segmenting the antiviral action into multiple mechanisms: nucleoside analogs for viral load reduction and small molecule compounds (Formula I) with novel chemical structures for alternative antiviral activity. This segmentation allows each component to target different aspects of HBV, reducing the emergence of resistance through multi-target pressure.
Solution Approach 2:
The invention creates a composite treatment regimen combining conventional nucleoside analogs with newly discovered small molecule compounds having specific chemical formulas (Formula I). This composite approach integrates different pharmacological mechanisms - nucleoside incorporation into viral DNA and small molecule interference with viral replication - to achieve synergistic antiviral effects while minimizing resistance development.
2Productivity
If current FDA-approved drugs are used, then viral replication is suppressed, but cccDNA persists in hepatocytes preventing cure
Solution Approach 1:
The patent introduces small molecule compounds (Formula I) that act preliminarily on cccDNA before it can serve as a persistent template for viral replication. These compounds interfere with cccDNA maintenance or conversion processes, preventing the reservoir from sustaining long-term infection, thereby enabling potential functional cures when combined with nucleoside analogs.
Solution Approach 2:
The small molecule compounds serve as intermediaries that bridge the gap between suppressing active viral replication and eliminating the cccDNA reservoir. They mediate antiviral effects by targeting intermediate steps in the viral life cycle that connect replicating virus to persistent cccDNA, thereby disrupting the cycle that maintains chronic infection.
3Quantity of substance
If high doses of antiviral agents are administered, then viral load reduction is enhanced, but tolerability and safety issues arise
Solution Approach 1:
The patent merges low-dose nucleoside analog therapy with low-dose small molecule compound therapy to achieve high-dose equivalent antiviral effect. By combining two different mechanisms of action, each can be administered at lower doses while collectively producing superior viral load reduction compared to high-dose monotherapy, thereby improving tolerability.
Data Source
AI summary
The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.